Table 4

Parameter values from two-compartment model analysis of sulindac sulfone plasma concentration-time profiles, after the first dose and after the 6-month dose

The average concentration for each dosage was analyzed. The last two rows represent the same data, expressed in differing units.

ParameterUnits200 mg300 mg400 mg
baseln6 mobaseln6 mobaselnabaselnb6 mob
V1/Fcliter32.611.313.915.135.710.39.44
Vss/Fcliter58.736.449.442.955.192.854.2
t 1/2 abs h0.630.620.620.840.570.530.52
T lag h0.6550.3690.3770.4200.2110.2420.827
CL/Fcl/h6.784.576.684.938.464.456.16
AUCμM× h78.9118121164127241174
T 1/2 h9.407.777.908.546.032110.9
T max h2.281.411.371.811.691.061.61
C max mg/l3.758.628.5210.006.7714.817.9
C max μm10.123.122.926.918.239.748.1
  • a All six patients were analyzed for the first dose baseline.

  • b Only two patients ended the 6-month study still taking the 400-mg bid dosage; these base line and 6-month parameter sets were an analysis of the average C versus t profiles from these two patients: 2006 and 2008.

  • c F is the fraction of the oral dose that reaches the systemic circulation. Because the dose was administered orally, the value of F was unknown and potentially <1.00. This uncertainty in F was transmitted to the clearance and volume of distribution values, i.e., if F <1, then the clearance and volume of distribution values are larger than the true values. For this reason, these parameters were shown divided by F; F was omitted when the symbols were used in the text.